

Barts Health 2013-14 cost improvement programme

Update for Inner North East London Joint Health Overview and Scrutiny Committee 20 November 2013



Contents

- 1. Objective of our turnaround programme
- 2. Our Care Campaign
- 3. CIP assurance: patient safety and quality
- 4. The Barts Health CIP programme cycle
- 5. Themes of our CIP programme
- 6. Our progress so far
- 7. Our project management approach
- 8. Process for assessing CIP impact
- 9. Next steps



1. Objective of our turnaround programme

To sustain or improve the quality of patient care, increase the speed of delivery, whilst improving efficiencies and reducing costs so that we are able to live within our annual budgets and meet our operating commitments.

Our mission and values

To be clear - we are not altering our mission. This is to change lives in east London through delivering excellent healthcare, reducing health inequalities and improving health in our local populations. To be just as clear - we will stay true to the values that the board and the organisation have committed to.

There is no room for deviation from our mission or our values

2. Barts Health Care Campaign #becausewecare

- We need to radically improve the quality and safety of our services in order to improve community confidence and trust in Barts Health
- The care campaign is our opportunity to relentlessly focus on our patients' best interests, to keep patients safe and to create a climate of care where:
 - saying "that's wrong" is right (openness, transparency and candour)
 - we relentlessly pursue excellence in care (fundamental standards and beyond)
 - working together is the norm
 - learning is at the centre of all we do
 - compassionate, caring and committed nurses, midwives and AHPs is the norm
 - we develop our leaders and support them to be focused on the right things

Barts Health #becausewecare

PATIENTS

2. Barts Health Care Campaign

#becausewecare

Our objectives

Best Leadership **Environment/cleanliness C**omplaints matter Accreditation Upholding our values **S**afety first – deteriorating patients Eliminating falls and pressure ulcers Welcoming and listening to patient and staff feedback Everyone matters - team meetings, appraisal and supervision **C**aring with compassion Assurance – check outcomes and drive improvements **R**isks are well managed Economical – cost effectiveness and productivity

Barts Health #becausewecare





3. CIP Assurance: Patient Safety & Quality

Quality Assurance & Independent Panels

What is the process for approving schemes? How is the Independent Panel process working? Process required to approve schemes prior to Chief Nurse and Medical Director sign-off. There have been over 30 Independent Panels to date, reviewing CIP schemes for approval. As at the time of the last Board, £47M of schemes had been approved. It is anticipated that by the Trust Board on 28th August 2013, that additional schemes will be approved, resulting in an overall CIP value (FYE) of £77.5M.

Letters of What are they, and what was representation the process for clinical signoff ? Each CAG has provided a letter of representation, as part of the clinical signoff process for CIPs, to provide assurance to the Board that the necessary systems and processes are in place within the CAG, to ensure that no CIP has a negative impact on patient safety. Schemes are ultimately approved by the Chief Nurse and Medical Director and the Trust Board.

CSL

CSUs and CCG' What assurance is - assurance

D

Α

В


Risks, Quality & KPI's for CIPs: Linking to our performance & on-going assurance The NHS England provider assurance framework sets out requirements for ensuring safe delivery of CIPs . We have been allocated a current Green-Amber rating, and we are continuing to work with the CCGs and the CSU to receive assurance of our CIP process. They will be seeking evidence of our process in practice on an on-going basis, and will be reviewed via the commissioner led Clinical Quality Review Meetings. (CQRMs).


The Trust will be reviewing performance and incident indicators, to assess ant potential link to the CIP programme, and identifying any linkages or route causes of performance issues or incidents etc which are directly linked to CIP implementation. Each CAG will monitor this through their boards, but this will also feature as part of their performance review meetings, with regular updates and oversight provided to the Quality Assurance Committee.

4. The Barts Health CIP programme cycle

Barts Health CIP Programme cycle


The below diagram and process flow shown to the right, demonstrate the systems and processes adopted for CIPs, from identification, through to clinical sign-off, implementation and review.







5. Themes of our CIP programme



6. Our progress so far

•	£60.9m part year effect
	CIPs now identified

In addition:

- Non-recurrent schemes with a value of £2.7M inyear also identified
- Cost avoidance schemes with a value of £0.4m inyear also identified
- Total identified workstreams, cost avoidance and nonrecurrent schemes is £64.1M

	TOTAL		
Workstream	Total savings	Total Full Yea	
workstream	identified 13-14	Effect Savings	
CAG specific scheme	12,819,697	16,679,196	
Corporate	1,571,624	1,620,420	
Corporate Specific	418,709	1,531,832	
Diagnostics	738,723	751,987	
Estates & Facilities	4,083,667	5,016,004	
Income	3,429,771	3,995,211	
Length of Stay	3,974,081	5,463,100	
Medical Workforce: Job plans/ Capacity & demand reviews	1,324,516	1,839,482	
Medical Workforce: Junior Docs rotas & banding reviews	1,024,003	1,125,569	
Outpatients	624,143	1,025,114	
Pharmacy	2,784,619	3,243,580	
Procurement	4,661,942	6,270,345	
Theatres	947,085	3,115,949	
Variable Pay – Bank and Agency use, inc vacancy fill-rate	817,224	1,234,812	
Variable pay: Medical Workforce: Additional payments,	243,657	163,140	
Workforce: Additional payments, inc Variable Pay	212,798	367,800	
Workforce: CAG Leadership	803,043	2,016,981	
Workforce: Clinical A&C & Clinical A&C (Other)	1,297,527	1,490,073	
Workforce: Nursing (Ward based/ Non ward)	4,473,967	6,598,124	
Workforce: Spans of control	14,662,567	15,573,588	
Grand Total	60,913,364	79,122,305	

7. CIP Assurance: Project management



Exec Sponsor: Michael Pantlin Workstream Lead: Sue Lewis Finance Support: Simon Co Other Support: Target 2013/14 € tRLH - new rote in place 52.50 sticing SS Patholog Workforce Nursing (Ward based) 1.01 130 days* 130 days 23 days 63 days 60 days 60 days 60 days 60 days 60 days Men 25/02/11 Men 25/02/13 Men 25/02/13 Men 25/02/13 Men 12/04/13 Men 12/04/13 Men 12/06/13 Men 10/06/13 Men 10/06/13 47,420 333,333 11,000 7,416 ix review - nursing (6 to 5s' 6,00 isto - Band & Clinical Scientist on call rate 114 fran 37,50 nning to harmoniae LOING - Replace 10 PA's of utrasound work undertake Agency (take out budget) - all service lines 817,229 200,000 40,000 24 [1] 23 days 23 days 60 days 2 Project Plan Mag 12/20/12 33 23 days 25 days 23 days Mon 25/02/1 Mon 25/02/13 Mon 25/02/13 25 days 25 days 25 days 25 days 180 days 25 days Mon 25/02 Mon 25/02 Mon 25/02/13 WHIT 14 Effect 13/14 Effect Level 1,634,128 64,047 832,723 1,571,624 64,047 20,855 1,620,420 48,504 14,000 1,638,788 64,047 844,171 4,944,671 3,995,211 5,403,100 1,835,410 1,835,410 1,835,410 3,311,989 7,176,745 5,073,193 1,426,518 791,926 64,044 416,868 395,000 406, 448 ates & Facilitie 3.326.279 3.681.008 689,056 754,387 97,979 861.004 68.332 68.332 4,083,667 1,072,763 1,002,168 \$65,439 1.602.622 1,602,622 3,429,771 1,602,622 561,667 357,712 164,593 45,000 357,821 1,602,622 614,667 512,323 576,344 45,000 2,227,732 2,744,700 593,712 301,399 144,464 1.496.703 1.869.01 4.384.08 ob plans/ Capacity & demand revie 821,688 784,563 955,800 1,379,400 1,141,156 45,000 Delivery update 868,90 2,293,515 2.411.002 135,326 748,254 437,710 391,735 25,000 35,750 22,785 28,704 2,834,447 3.619.635 829,861 4,092,036 1.254,155 1.776.033 41,666 136.419 161.296 5,794,213 4,092,036 817,224 417,588 163,140 367,800

408,612

408,612 609,294 243,657 212,798 108,434

Quality & Safety

review

108.633 1.254.46 2.573.179 3.085.868

iable pay: Medical Workforce: Additional paym orce: Additional payments, inc Variable Pay

force: CAG Leadership

irce: Spans of control

rkforce: Clinical A&C kforce: Clinical A&C & Clinical A&C (Other) 994,928

207.93 817, 224 545, 129

476,324 52,500

CIPs - Quality Re

52,50


1.403.540

817,224 719,981

Each CIP plan is underpinned by a project team, with a financial plan and project plan Reviews of financial performance and impacts on quality and safety are also undertaken

8. Assessing impact of CIPs on quality and safety

Barts Health has developed a user-friendly process for undertaking a quality impact assessment across a number of domains to access CIP impact.



Quality

& Safety

Quality and safety impact assessment prior to clinical sign-off and CIP implementation Quality impact assessment

assesses CIP impact on six main domains:

- Patient Safety
- Clinical outcomes
- Patient Pathways
- Patient Experience
- Accessibility
- Staff

Any negative impacts identified must be mitigated, with detailed actions.

A CIP with negative impact on patient safety will not be approved

8. Risk assessing our CIPs

Barts Health has in place a business-as-usual process for undertaking risk assessments. This has been adopted for undertaking CIP risk assessments.

1.	Include the	e name/ ref number for your CIP	as ı	useo	d or	n the tracker Tab			1 - Rare	Unlikely	Possible	4 - Likely	certain
							5 - Catastrop	hic	5	10		20	25
	2. From	the drop-down list, categorise the	risk	ass	sess	ment you are	4 - Major 3 - Moderate		4	8	12	16	20
СС		- either service provision risk pos		-	2 – Minor		ა ი	0	9	12 8	15 10		
	1 0	risk to delivery of the	1-	, .	1 - Negligible	e	2 1	2	3	-	5		
		from the drop-down. For f		4	. Fo	refer to the Instructions or all risks, ensure that mi mitigation is completed.	tigating actio A deadline f should b	or co	mpletin		ला an anticipa		
CIP Scheme			Likelihood	Consequence	Risk Rate	N.1:+:	gating action	Likelihood Consequence	Risk Rate	adline	Owner		15+ risk added to datix
Reference number:	TYPE 1 TYPE 2 Select from dropdown	Risk Description		S				C	De	aume	G when	updated	
Reference	TYPE 2 Select from	Risk Description	3		9	IVII (I		2 2					YES/NO/
Reference	TYPE 2 Select from	Risk Description	3		<mark>9</mark> 0								YES/NO/

Section 8


Page 10

8. Ongoing monitoring of CIPs: Impact on quality and safety

Reactive

All CAGs are required to consider all incidents and complaints in light of implemented CIPs


CAGs will consider linkages between CIPs and incidents and complaints via their business as usual governance processes. In addition, CAGs will be requested to complete a monthly CIP quality dashboard report, which will detail the number of CIPs linked to incidents and complaints, and the course corrective actions taken.



Proactive

All CAGs are required to continue to quality impact assess all CIPs via Quality Impact Assessments

All CIPs continue to be required to be underpinned by a completed Quality Impact Assessment. Any CIP identifying a potential negative impact MUST be supported by a mitigating plan to reduce the impact.



9. Next steps for the programme

- Continue to monitor any impacts on quality and safety as a result of CIP implementation
- Continue to identify, approve and implement new schemes, in order to fulfil our CIP requirement
- Continue with our programme management arrangements to ensure CIP identification and delivery
- Continue to engage with our stakeholders and communicate details of our programme

